Cell cycle inhibitors for the treatment of NSCLC

Bibliography

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917
   PubMed Web of Science ®Google Scholar
• Maziak DE, Markman BR, MacKay JA, et al. Cancer care ontario practice guidelines initiative lung cancer disease site G. Photodynamic therapy in nonsmall cell lung cancer: a systematic review. Ann Thorac Surg 2004;77(4):1484-91
   PubMedGoogle Scholar
• Edward C, Halperin C, Brady LW. Perez and brady's principles and practice of radiation oncology. Wolters Kluwer Lippincott Williams and Wilkins, Philadelphia; 2008
   Google Scholar
• National Cancer Institute: SEER Cancer Statistics Review, 1973-2008. US National Institutes of Health
   Google Scholar
• Eymin B, Gazzeri S. Role of cell cycle regulators in lung carcinogenesis. Cell Adh Migr 2010;4(1):114-23
   PubMed Web of Science ®Google Scholar
• Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28(Suppl 4):3-13
   PubMedGoogle Scholar
• Geradts J, Hu SX, Lincoln CE, et al. Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. Int J Cancer 1994;58(2):161-7
   PubMedGoogle Scholar
• Marchetti A, Doglioni C, Barbareschi M, et al. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 1998;75(2):187-92
   PubMed Web of Science ®Google Scholar
• Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996;73(3):294-300
   PubMed Web of Science ®Google Scholar
• Gautschi O, Ratschiller D, Gugger M, et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007;55(1):1-14
   PubMed Web of Science ®Google Scholar
• Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001;34(2):207-18
   PubMedGoogle Scholar
• Muller-Tidow C, Metzger R, Kugler K, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001;61(2):647-53
   PubMedGoogle Scholar
• Dosaka-Akita H, Hommura F, Mishina T, et al. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res 2001;61(6):2500-4
   PubMedGoogle Scholar
• Cooper WA, Kohonen-Corish MR, McCaughan B, et al. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology 2009;55(1):28-36
   PubMedGoogle Scholar
• Dobashi Y, Shoji M, Jiang SX, et al. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998;153(3):963-72
   PubMed Web of Science ®Google Scholar
• Yoshida T, Tanaka S, Mogi A, et al. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004;15(2):252-6
   PubMed Web of Science ®Google Scholar
• Soria JC, Jang SJ, Khuri FR, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000;60(15):4000-4
   PubMed Web of Science ®Google Scholar
• Xu HT, Ma L, Qi FJ, et al. Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma. Pathol Int 2006;56(7):375-80
   PubMed Web of Science ®Google Scholar
• Hilton JF, Shapiro GI. Aurora kinase inhibition as an anticancer strategy. J Clin Oncol 2014;32(1):57-9
   PubMed Web of Science ®Google Scholar
• Mariatos G, Bothos J, Zacharatos P, et al. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Res 2003;63(21):7185-9
   PubMedGoogle Scholar
• Gemma A, Seike M, Seike Y, et al. Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer. Genes Chromosomes Cancer 2000;29(3):213-18
   PubMedGoogle Scholar
• Nomoto S, Haruki N, Takahashi T, et al. Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. Oncogene 1999;18(50):7180-3
   PubMedGoogle Scholar
• Marsit CJ, Kim DH, Liu M, et al. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence. Int J Cancer 2005;114(2):219-23
   PubMedGoogle Scholar
• Zhang P, Wang J, Gao W, et al. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer 2004;3:14
   PubMed Web of Science ®Google Scholar
• Seymour L. Novel anti-cancer agents in development: exciting prospects and new challenges. Cancer Treat Rev 1999;25(5):301-12
   PubMedGoogle Scholar
• Sausville EA, Zaharevitz D, Gussio R, et al. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol Ther 1999;82(2-3):285-92
   PubMedGoogle Scholar
• Senderowicz AM. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Hematol Oncol Clin North Am. 2002;16(5):1229-53
   Google Scholar
• Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92(10):3804-16
   PubMedGoogle Scholar
• Kitada S, Zapata JM, Andreeff M, et al. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96(2):393-7
   PubMed Web of Science ®Google Scholar
• Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001;7(12):4209-19
   PubMedGoogle Scholar
• Shapiro GI, Koestner DA, Matranga CB, et al. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1999;5(10):2925-38
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001;7(6):1590-9
   PubMed Web of Science ®Google Scholar
• Galimberti F, Thompson SL, Liu X, et al. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res 2010;16(1):109-20
   PubMed Web of Science ®Google Scholar
• Fleming IN, Hogben M, Frame S, et al. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin Cancer Res 2008;14(13):4326-35
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96(1):29-37
   PubMed Web of Science ®Google Scholar
• Siegel-Lakhai W, Rodenstein D, Beijnen J. Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005;23:2060
   Google Scholar
• Terret C, Zanetta S, Roche H, et al. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early clinical study group (ECSG). Eur J Cancer 2003;39(8):1097-104
   PubMedGoogle Scholar
• Talbot DC, von Pawel J, Cattell E, et al. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2007;13(6):1816-22
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3(11):1427-38
   PubMed Web of Science ®Google Scholar
• Nemunaitis JJ, Small KA, Kirschmeier P, et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 2013;11(1):259
   PubMed Web of Science ®Google Scholar
• Raghavan P, Tumati V, Yu L, et al. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. Int J Radiat Oncol Biol Phys 2012;84(4):e507-14
   PubMed Web of Science ®Google Scholar
• Degrassi A, Russo M, Nanni C, et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. Mol Cancer Ther 2010;9(3):673-81
   PubMed Web of Science ®Google Scholar
• Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5(6):429-40
   PubMed Web of Science ®Google Scholar
• Wolf G, Elez R, Doermer A, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997;14(5):543-9
   PubMed Web of Science ®Google Scholar
• Ellis PM, Chu QS, Leighl NB. A phase I dose escalation trial of BI2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2008;26:8115
   Google Scholar
• Sebastian M, Reck M, Waller CF, et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010;5(7):1060-7
   PubMed Web of Science ®Google Scholar
• Gil T, Schoffski P, Awada A. Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. J Clin Oncol (suppl) 2010;28:3061
   PubMedGoogle Scholar
• Dumez H, Gombos A, Schöffski P. Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. J Clin Oncol 2012; 30(Suppl):abstract 3018^
   Google Scholar
• Vazquez A, Bond EE, Levine AJ, et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7(12):979-87
   PubMed Web of Science ®Google Scholar
• Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1(3):233-40
   PubMed Web of Science ®Google Scholar
• Takimoto R, Wang W, Dicker DT, et al. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002;1(1):47-55
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Issaeva N, Zache N, et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005;280(34):30384-91
   PubMedGoogle Scholar
• Sun Y. p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 2006;45(6):409-15
   PubMedGoogle Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
   PubMed Web of Science ®Google Scholar
• Wang W, Takimoto R, Rastinejad F, et al. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003;23(6):2171-81
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8(3):282-8
   PubMed Web of Science ®Google Scholar
• Magrini R, Russo D, Ottaggio L, et al. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. J Cell Biochem 2008;104(6):2363-73
   PubMedGoogle Scholar
• Rao CV, Patlolla JM, Qian L, et al. Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. Neoplasia 2013;15(9):1018-27
   PubMedGoogle Scholar
• Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91(9):763-71
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Soliman H, Janssen WE, et al. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010;10(6):983-91
   PubMed Web of Science ®Google Scholar
• Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010;16(2):376-83
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Donehower RC, Iyengar T, et al. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs 2013;31(1):136-44
   PubMedGoogle Scholar
• Mitchell JB, Choudhuri R, Fabre K, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010;16(7):2076-84
   PubMed Web of Science ®Google Scholar
• Ho A, Bendell J, Cleary J. Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients with advanced solid tumors. J Clin Oncol 2011;29(Suppl 15):3033
   Google Scholar
• Sausville E, Barker P, Agbo F. Phase I dose-escalation study ofAZD7762 in combination with gemcitabine (gem) in patients with advanced solid tumors. J Clin Oncol 2011;29(Suppl 15):3058
   Google Scholar
• Daud A, Springett G, Mendelson D. A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1(CHK1),in combination with gemcitabine (Gem) in subjects with advanced solid tumors. J Clin Oncol 2010;28(Suppl 15):3064
   Google Scholar
• Brega N, McArthur G, Britten C. Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase. J Clin Oncol 2010;28(Suppl 15):3062
   Google Scholar
• Neijenhuis S, Verwijs-Janssen M, van den Broek LJ, et al. Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}. Cancer Res 2010;70(21):8706-14
   PubMedGoogle Scholar
• Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 2003;17(5):615-28
   PubMedGoogle Scholar
• Jones C, Blades K, Foote K. Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients. Cancer Res 2013;73(Suppl 8):2348
   Google Scholar
• Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010;10(12):825-41
   PubMed Web of Science ®Google Scholar
• Casaluce F, Sgambato A, Maione P, et al. Emerging mitotic inhibitors for non-small cell carcinoma. Expert Opin Emerg Drugs 2013;18(1):97-107
   PubMed Web of Science ®Google Scholar
• Lee P, Alvarez R, Melichar B. Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: preliminary phase II results. J Clin Oncol (ASCO Annual Meeting Proceedings) 2012;30(Suppl):3010
   Google Scholar
• Friedberg JW, Mahadevan D, Cebula E, et al. Phase II Study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-hodgkin lymphomas. J Clin Oncol 2014;32(1):44-50
   PubMed Web of Science ®Google Scholar
• Stone A, Sutherland RL, Musgrove EA. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit Rev Oncog 2012;17(2):175-98
   PubMedGoogle Scholar
• George S, Kasimis BS, Cogswell J, et al. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 2008;9(3):160-5
   PubMed Web of Science ®Google Scholar
• Warren SL, Nemunaitis J, Stephenson J. A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC). Cancer Res (Supplement) 2011;71:2242
   Google Scholar
• Weiss GJ, Hidalgo M, Borad MJ, et al. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs 2012;30(6):2334-43
   PubMed Web of Science ®Google Scholar
• Ellis PM, Chu QS, Leighl N, et al. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin Lung Cancer 2013;14(1):19-27
   PubMed Web of Science ®Google Scholar
• Seto T, Esaki T, Hirai F, et al. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 2013;72(3):619-27
   PubMed Web of Science ®Google Scholar
• Seto T, Esaki T, Hirai F, et al. Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. J Clin Oncol 2012;30(Suppl):abstract 3045
   Google Scholar
• Sausville EA, LoRusso P, Carducci MA, et al. Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. J Clin Oncol 2011;29(Suppl):abstract 3058
   Google Scholar
• Ho A, Bendell J, Cleary J, et al. Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid turmors. J Clin Oncol 2011;29(Suppl):3033
   Google Scholar
• Brega N, McArthur G, Britten C, et al. Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase. J Clin Oncol 2010;28(Suppl):3062
   Google Scholar
• Daud A, Springett GM, Mendelson DS, et al. A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. J Clin Oncol 2010;28(Suppl):abstract 3064
   Google Scholar
• Mross KB, Scheulen ME, Frost A, et al. A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. J Clin Oncol 2010;28(Suppl):3011
   Google Scholar
• Gauler TC, Besse B, Novello S, et al. Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). J Clin Oncol 2013;31(Suppl):e19138
   Google Scholar